← Back to Search

Ablative Therapy for Oligoprogressive Genitourinary Cancers (LAYOVER Trial)

N/A

Recruiting

Led By Mamta Parikh, MD, MS

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

≤ 5 progressing or new metastatic lesions

Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies: Cohort A: prostate cancer, Cohort B: urothelial carcinoma, Cohort C: renal cell carcinoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months from the first day of ablative local therapy

Awards & highlights

LAYOVER Trial Summary

This trial studies if adding local therapy to systemic treatment can help treat cancer that is not progressing quickly. Primary outcome is time until treatment stops working.

Who is the study for?

This trial is for adults over 18 with certain genitourinary cancers (prostate, bladder, or kidney) that have spread but are limited to 5 new or worsening spots. They must be on a systemic therapy that's been working for at least 3 months and can continue after local treatment. People can't join if they have health issues preventing local therapy or had bad reactions to such treatments before.Check my eligibility

What is being tested?

The study tests the benefit of adding targeted local therapies to ongoing systemic cancer treatments in patients whose cancer has mostly been controlled but started progressing in up to five areas. The main goal is seeing how long patients can go without their treatment failing after this combination.See study design

What are the potential side effects?

While specific side effects aren't listed here, locally ablative therapies generally may include pain at the treatment site, fatigue, skin changes like redness or blistering, and potential damage to nearby organs depending on where the treatment is aimed.

LAYOVER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have 5 or fewer new or worsening cancer spots.

Select...

I have been diagnosed with prostate, bladder, or kidney cancer.

Select...

I am 18 years old or older.

LAYOVER Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months from the first day of ablative local therapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months from the first day of ablative local therapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months from the first day of ablative local therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with controlled disease

Secondary outcome measures

Median overall survival

Number of participants experiencing grade ≥ 3 adverse events attributable to ablative local therapy

Time to treatment failure

LAYOVER Trial Design

1Treatment groups

Experimental Treatment

Group I: Ablative local therapyExperimental Treatment1 Intervention

Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

911 Previous Clinical Trials

4,709,369 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,672 Previous Clinical Trials

40,926,291 Total Patients Enrolled

Mamta Parikh, MD, MSPrincipal InvestigatorUniversity of California, Davis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers are involved with this investigation?

"Affirmative. According to the clinicaltrials.gov, this medical study is currently inviting participants. The trial was launched on October 5th 2023 and was recently modified on October 19th 2023; 150 patients are being recruited from one location."

Answered by AI

Is participation in this trial available at the present time?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, which was posted on October 5th 2023, is currently enrolling participants. One hundred fifty people must be recruited from 1 medical location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

Mamta Parikh 2023. "Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06101290.